
    
      Between 2014 and 2019, 41 metastatic GIST patients received regorafenib therapy. 35 out of 41
      metastatic GIST patients who were on regorafenib therapy facing progression and 15
      experienced local progression underwent salvage surgery. Thirty-five of 41 (85.4 %)
      pre-treated GIST patients receiving regorafenib who experienced disease progression after a
      median follow-up of 12.4 months of regorafenib use. 15 out of 35 (42.9%) metastatic GIST
      patients receiving regorafenib facing progression underwent salvage surgery.
    
  